{"id":64744,"date":"2025-02-17T12:01:19","date_gmt":"2025-02-17T12:01:19","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/02\/17\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/"},"modified":"2025-02-17T12:01:19","modified_gmt":"2025-02-17T12:01:19","slug":"3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/","title":{"rendered":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy"},"content":{"rendered":"<div>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">REYKJAVIK, Iceland<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 17, 2025<\/span><\/span> \/PRNewswire\/ &#8212; 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel\u00a0 blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z&#8217;s cutting-edge high-throughput drug discovery platform and introduce new avenues for non-stimulant-based ADHD treatment.<\/p>\n<p>ADHD is a prevalent neurodevelopmental disorder with limited treatment options. Current stimulant medications, such as methylphenidate, offer benefits to some but are often associated with side effects, abuse potential, and a high non-response rate. 3Z Pharmaceuticals is committed to addressing these gaps by pioneering alternative, non-stimulant therapeutics.<\/p>\n<p>In this newly published study, researchers at 3Z, integrated cross-species behavioral assays, Mendelian Randomization analysis, and human genetic data to demonstrate amlodipine&#8217;s therapeutic potential. Key findings include:<\/p>\n<ul type=\"disc\">\n<li>Behavioral Rescue in ADHD Models: Amlodipine significantly reduced hyperactivity in Spontaneously Hypertensive Rats and improved impulsivity in the adgrl3.1-\/- zebrafish model of ADHD, providing cross-species validation of its efficacy.<\/li>\n<li>Blood-Brain Barrier Penetration &amp; Neural Impact: Surprisingly traditional penetration studies confirmed that amlodipine crosses the blood-brain barrier, where it modulates neuronal activation, countering the assumption of poor brain penetration.<\/li>\n<li>Genetic Evidence via Mendelian Randomization: Human genetic analysis linked ADHD risk to variations in LTCC genes (CACNA1C, CACNB1, CACNA2D3), which are direct targets of amlodipine, reinforcing its mechanistic potential in ADHD therapy.<\/li>\n<li>Clinical Relevance in Human Populations: Polygenic risk score analysis using the UK Biobank demonstrated that individuals with a high ADHD genetic burden who were prescribed amlodipine exhibited reduced ADHD-related symptoms, independent of its antihypertensive effects.<\/li>\n<\/ul>\n<p>Dr. <span class=\"xn-person\">Karl Karlsson<\/span> a neuroscientist, CEO of 3Z Pharmaceuticals and Professor of Biomedical Engineering at <span class=\"xn-location\">Reykjavik<\/span> University, commented on the study&#8217;s impact:<\/p>\n<p><i>&#8220;This research represents a paradigm shift in ADHD therapeutics. Our findings not only validate the mechanism impacted by amlodipine as a promising candidate for non-stimulant ADHD treatment but also underscore the power of our high-throughput screening and genetic modeling approaches, performed in close alliance with biotx.ai. This is an exciting step forward in our mission to deliver more effective and well-tolerated treatments for ADHD.&#8221;<\/i><\/p>\n<p>Building on these findings, 3Z Pharmaceuticals is advancing a variant of the therapeutic towards clinical development, leveraging its established safety profile and precise mechanism of action to introduce transformative ADHD therapy.<\/p>\n<p><b>Media Contact:<br \/><\/b>Name: Karl \u00c6gir Karlson<br \/>Title: CEO<br \/>3Z Pharmaceuticals<br \/>Email: <a href=\"mailto:Karlsson@3z.is\" target=\"_blank\" rel=\"nofollow\">Karlsson@3z.is<\/a><br \/>Phone: +354-8256467<\/p>\n<p>Link to paper:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4363821-1&amp;h=1283987419&amp;u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41386-025-02062-x&amp;a=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41386-025-02062-x\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.nature.com\/articles\/s41386-025-02062-x<\/a><\/p>\n<p>This information was brought to you by Cision <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4363821-1&amp;h=2688366151&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" target=\"_blank\" rel=\"nofollow\">http:\/\/news.cision.com<\/a><\/p>\n<p><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4363821-1&amp;h=518239132&amp;u=https%3A%2F%2Fnews.cision.com%2F3z-ehf%2Fr%2F3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adh%2Cc4106638&amp;a=https%3A%2F%2Fnews.cision.com%2F3z-ehf%2Fr%2F3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adh%2Cc4106638\" target=\"_blank\" rel=\"nofollow\">https:\/\/news.cision.com\/3z-ehf\/r\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adh,c4106638<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>REYKJAVIK, Iceland, Feb. 17, 2025 \/PRNewswire\/ &#8212; 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel\u00a0 blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z&#8217;s cutting-edge high-throughput drug [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-64744","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy\" \/>\n<meta property=\"og:description\" content=\"REYKJAVIK, Iceland, Feb. 17, 2025 \/PRNewswire\/ &#8212; 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychophar\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-17T12:01:19+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy\",\"datePublished\":\"2025-02-17T12:01:19+00:00\",\"dateModified\":\"2025-02-17T12:01:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/\"},\"wordCount\":447,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/\",\"name\":\"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-02-17T12:01:19+00:00\",\"dateModified\":\"2025-02-17T12:01:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/","og_locale":"en_US","og_type":"article","og_title":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy","og_description":"REYKJAVIK, Iceland, Feb. 17, 2025 \/PRNewswire\/ &#8212; 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychophar","og_url":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-02-17T12:01:19+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy","datePublished":"2025-02-17T12:01:19+00:00","dateModified":"2025-02-17T12:01:19+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/"},"wordCount":447,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/","url":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/","name":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-02-17T12:01:19+00:00","dateModified":"2025-02-17T12:01:19+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/64744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=64744"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/64744\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=64744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=64744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=64744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}